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Editorial Comment 
Combination Therapy for 
Angina Pectoris* 
JOEL S. KARLINER, MD, FACC 
San FrancIsco, California 
In recent years a variety of new agents have become avail•
able for the therapy of angina pectoris. Among the most 
prominent of these are the calcium entry blocking agents, 
which currently occupy a key role in the treatment of both 
acute and chronic ischemic heart disease. Both beta-adre•
nergic antagonists and the calcium entry blockers have been 
utilized as monotherapy for angina pectoris, but there has 
not been good objective evidence to demonstrate the clinical 
superiority of one class of agent over the other. Thus, the 
choice must currently be made on the basis of the side effect 
profile as well as, in some instances, on economic 
considerations. 
Considerable evidence suggests that combination therapy 
utilizing both classes of agents may be more effective than 
monotherapy, particularly in patients whose condition is 
refractory to one type of agent or who are unable to tolerate 
higher doses of one class. Typically, a calcium entry blocker 
has been added to a beta-adrenergic antagonist. The current 
study of Humen et al. (1) has extended a prior study by the 
same group (2) in which it was concluded that propranolol 
and diltiazem should be considered the combination of choice 
because of their low incidence of adverse clinical effects. 
The current study of Humen et al. (I) demonstrates the 
superiority of the combination of high dose (360 mg/day) 
diltiazem with propranolol in doses that produced' 'full beta 
blockade, " defined as a maximal heart rate of less than 120 
beats/min during stress testing and a propranolol dose of at 
least 160 mg/day. Although one may question the definition 
of "full beta blockade," the evidence is impressive, both 
subjectively and objectively, that high dose diltiazem ther•
apy in combination with propranolol produced better relief 
of ischemic heart disease than did propranolol alone or pro•
pranolol in combination with diltiazem at a dose of 240 
mg/day. 
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Limitations of study. The study demonstrates one les•
son of such investigations-the variability of angina pec•
toris. Thus, even with the requirement for entry into the 
study that angina must be present in the face of beta block•
ade, 25% of the patients were no longer limited by angina 
during the course of the investigation, despite receiving 
identical therapy during the double-blind phase. 
A design flaw of the current report is that no placebo 
measurements were made, although these were included in 
the previous study by the same group (2). Furthermore, by 
not testing high dose diltiazem (360 mg/day) alone, the 
current study does not show that combination therapy is 
superior to monotherapy with high dose diltiazem. This 
issue was addressed by Hung et al. (3), who noted that 
diltiazem alone, 90 mg four times/day, was as effective as 
either moderate dose propranolol (60 mg four times/day) or 
the combination of diltiazem and propranolol in improving 
exercise tolerance, reducing myocardial ischemia and in•
creasing left ventricular function in patients with stable an•
gina. Diltiazem at a dose of 360 mg/day is effective mono•
therapy (4-7) and as much as 480 mg/day in divided doses 
is well tolerated and highly effective in some patients who 
do not respond to other treatment. Thus, the study would 
have been more useful had the design included a comparison 
of propranolol and high dose diltiazem therapy with high 
dose diltiazem treatment alone. 
Rationale and combined advantages of combined 
therapy. Nevertheless, there are good reasons for the use 
of combination therapy. Thus, Pfisterer et al. (8) demon•
strated in humans a regional anti-ischemic effect of sublin•
gual nitroglycerin and intravenous nifedipine and metopro-
101, as evidenced by improved regional left ventricular 
function. They concluded that despite the similar anti-isch•
emic effects of all three drugs, the underlying hemodynamic 
mechanisms were quite different, thus providing a rationale 
for combined forms of therapy. More recently, Matsuzaki 
et al. (9) demonstrated in a single vessel chronic coronary 
stenosis model in the conscious dog that the combination 
of atenolol and diltiazem was significantly better than either 
drug alone in reducing ischemia. They hypothesized that 
atenolol substantially reduced myocardial oxygen con•
sumption of the left ventricle while the vasodilator action 
of diltiazem increased perfusion to the ischemic zone, either 
directly or through an increase of blood flow in coronary 
collateral vessels supplying that zone. A combination of 
reduced myocardial oxygen demand and augmentation of 
absolute blood flow to the ischemic zone thus improved 
distribution within that region in this animal model. 
Possible danger of congestive heart failure. Finally, 
the dangers of congestive heart failure produced by com•
bination therapy must be considered. Although both vera•
pamil and nifedipine in combination with beta-adrenergic 
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blockers have been reported to induce congestive heart fail•
ure in susceptible patients, the combination of diltiazem and 
propranolol has not been adequately studied, Diltiazem alone 
has been used with beneficial effects in severe congestive 
heart failure (10), and in the normal conscious dog, the 
combination of intravenous diltiazem and propranolol does 
not adversely affect left ventricular performance (11). Strauss 
et al. (12) recently reported on a patient who tolerated pro•
pranolol therapy without difficulty for many years and had 
an excellent response with high dose diltiazem monother•
apy; however. the combination of diltiazem and propranolol 
resulted in the development of congestive heart failure. Al•
though none of the patients studied by Humen et al. (I) had 
reduced left ventricular performance. one still must be ex•
ceedingly cautious when using the combination of a beta•
adrenergic antagonist with a calcium entry blocking agent 
such as diltiazem in the presence of overt or suspected 
congestive heart failure. 
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